CD28 and graft versus host disease: Importantly, a very recent study [63] on murine iTregs found that only iTregs induced by bead-bound anti-CD3/CD28 antibodies—and not by plate-bound CD3/CD28 antibodies—were stable for >7 days in vitro and in vivo and, consequently, could suppress murine GvHD in vivo.